Judith Heidebrink, M.D., M.S.
Richard D. and Katherine M. O'Connor Research Professor of Neurology
Clinical Professor, Neurology
Co-Division Chief, Alzheimer's Disease & Related Dementias
July 30, 2023
Exciting news released during Alzheimer’s Association International Conference
“The full FDA approval of lecanemab is a remarkable milestone in the treatment of Alzheimer’s disease. We now have a disease-modifying therapy approved based on its clinical benefit,” said Dr. Judy Heidebrink.
